Novo NVO and Pfizer PFE are both pharmaceutical giants based in Denmark and the United States, respectively, with broad portfolios spanning major therapeutic areas. Novo is widely recognized for its leadership in diabetes and obesity, with its semaglutide franchise marketed under the Ozempic and Rybelsus brands for type II diabetes (T2D) and Wegovy for chronic weight management. The company is also expanding its obesity offering with oral formulations, seeking to broaden its reach in the fast-growing weight-loss market. Pfizer, meanwhile, has traditionally maintained significant strength across oncology, vaccines, inflammation and immunology, rare diseases and other therapeutic areas.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.